Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) EBITDA Margin (2016 - 2025)

Zevra Therapeutics' EBITDA Margin history spans 9 years, with the latest figure at 27.27% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 15541.0% year-over-year to 27.27%; the TTM value through Dec 2025 reached 59.07%, up 30998.0%, while the annual FY2025 figure was 58.91%, 30890.0% up from the prior year.
  • EBITDA Margin reached 27.27% in Q4 2025 per ZVRA's latest filing, up from 15.87% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 57.44% in Q1 2021 to a low of 739.0% in Q3 2024.
  • Average EBITDA Margin over 5 years is 187.35%, with a median of 105.03% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: plummeted -46103bps in 2024, then surged 75487bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 110.07% in 2021, then rose by 17bps to 91.51% in 2022, then fell by -28bps to 117.31% in 2023, then decreased by -9bps to 128.14% in 2024, then soared by 121bps to 27.27% in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's EBITDA Margin are 27.27% (Q4 2025), 15.87% (Q3 2025), and 274.28% (Q2 2025).